← Back to headlines
Sanofi Halts Phase 3 Study of Riliprubart Due to Efficacy Concerns
Sanofi has stopped its phase 3 study of the drug riliprubart, intended for a rare nerve disease, citing concerns over its efficacy.
10 Jun, 05:52 — 10 Jun, 05:52
Sources
Showing 1 of 1 sources
